Matinas BioPharma Holdings (MTNB) Change in Account Payables (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Change in Account Payables of $397000.0 for Q1 2026, up 112.3% year-over-year from $187000.0 in Q1 2025, and up 68.94% quarter-over-quarter from $235000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Change in Account Payables (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Change in Account Payables data on file, last reported at $397000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $397000.0, up 112.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $430000.0 (up 325.13% YoY), and the FY2025 annual result was $220000.0, up 152.51% from the prior year.
- Change in Account Payables advanced to $397000.0 in Q1 2026 per MTNB's latest filing, from $235000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $414000.0 in Q1 2022 and troughed at -$855000.0 in Q2 2022.
- A 5-year average of -$13294.1 and a median of -$39000.0 in 2022 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables sank 3067.1% in 2022, then jumped 556.1% in 2025.
- A 5-year view of Change in Account Payables shows it stood at -$39000.0 in 2022, then sank by 720.51% to -$320000.0 in 2023, then rose by 20.62% to -$254000.0 in 2024, then surged by 192.52% to $235000.0 in 2025, then jumped by 68.94% to $397000.0 in 2026.
- Business Quant data shows MTNB's Change in Account Payables at $397000.0 in Q1 2026, $235000.0 in Q4 2025, and -$86000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | 397,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 397,000.00 |
| Mar 31, 2026 | 397,000.00 |
| Dec 31, 2025 | 235,000.00 |
| Dec 31, 2025 | 235,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -116,000.00 |
| Jun 30, 2025 | -116,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Mar 31, 2025 | 187,000.00 |
| Dec 31, 2024 | -254,000.00 |
| Dec 31, 2024 | -254,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Sep 30, 2024 | 111,000.00 |
| Jun 30, 2024 | -235,000.00 |
| Jun 30, 2024 | -235,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Dec 31, 2023 | -320,000.00 |
| Dec 31, 2023 | -320,000.00 |